Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Sarah A Lau-Braunhut, MD, Hannah Stone, Griffin Collins, MD, Sigbjørn Berentsen, MD PhD, Matt Zinter, MD, Benjamin Braun, MD PhD

Blood (2019) 134 (Supplement_1): 4798.

https://doi.org/10.1182/blood-2019-126365

Published: 2019

Journal Articles

Complement Inhibition with C1 Esterase Inhibitor Allowed Successful Transfusion of HLA Mismatched Platelets in a Transfusion Refractory Alloimmunized Patient: A Case Report

Maryam Sarraf Yazdy, MD, Catherine Broome, MD

Blood (2017) 130 (Supplement 1): 4845.

https://doi.org/10.1182/blood.V130.Suppl_1.4845.4845

Published: 2017

Journal Articles

Antibody-Mediated Immunosuppression Can Result from RBC Antigen Loss Independent of Fcγ Receptors in Mice

Amanda Mener, Seema R Patel, BS, PhD, Connie Arthur, PhD, Sean R Stowell, MD PhD

Blood (2017) 130 (Supplement 1): 2403.

https://doi.org/10.1182/blood.V130.Suppl_1.2403.2403

Published: 2017

Journal Articles

C3 Modulates RBC Antigen to Negatively Regulate Antibody Response

Amanda Mener, Connie M. Arthur, PhD, Seema R. Patel, PhD, Sean R. Stowell, MD PhD

Blood (2016) 128 (22): 22.

https://doi.org/10.1182/blood.V128.22.22.22

Published: 2016

Journal Articles

Microbial Exposure Regulates the Development of Anti-Blood Group Antibodies

Connie M. Arthur, PhD, Harold Clifford Sullivan, MD, Christian Gerner-Smidt, Nourine Ahmed-Kamili, Ashley Bennett, Seema R. Patel, PhD, Steve Henry, Sean R. Stowell, MD PhD

Blood (2016) 128 (22): 20.

https://doi.org/10.1182/blood.V128.22.20.20

Published: 2016

Journal Articles

Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease

Blood (2016) 128 (22): 387.

https://doi.org/10.1182/blood.V128.22.387.387

Published: 2016

Journal Articles

Complement Blockade with C1 Esterase Inhibitor in Refractory Immune Thrombocytopenia

Erin Elizabeth Roesch, MD, Catherine Broome, MD

Blood (2015) 126 (23): 2253.

https://doi.org/10.1182/blood.V126.23.2253.2253

Published: 2015

Journal Articles

N-Glycosylation Of Human ITP Autoantibodies Affects Complement Activation, Platelet Phagocytosis, and Platelet Survival In a Murine Model

Ulrich J. Sachs, MD, Kathrin Walek, Annika Krautwurst, Mathias J. Rummel, MD, Gregor Bein, MD, Sentot Santoso, PhD, Tamam Bakchoul, MD

Blood (2013) 122 (21): 569.

https://doi.org/10.1182/blood.V122.21.569.569

Published: 2013

Journal Articles

Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo

Reiko E Yamada, Kristopher K Steward, Gataree Ngarmchamnanrith, Sanjay Khare, Raj Sachdev, Iqbal Grewal, Sherie Morrison, John M Timmerman

Blood (2011) 118 (21): 2724.

https://doi.org/10.1182/blood.V118.21.2724.2724

Published: 2011

Journal Articles

GP IIb/Iiia-Dependent Complement Activation Is Common In Patients with Immune Thrombocytopenic Purpura.

Abdul Najaoui, Tamam Bakchoul, MD, Mathias J. Rummel, MD, PhD, Gregor Bein, MD, PhD, Sentot Santoso, PhD, Ulrich J. Sachs, MD, PhD

Blood (2010) 116 (21): 1430.

https://doi.org/10.1182/blood.V116.21.1430.1430

Published: 2010

Journal Articles

Erythropoietin Treatment Is Associated with Augmented Immune Response to the Influenza Vaccine in Hematologic Patients.

Howard S Oster, MD, PhD, Sara Prutchi-Sagiv, PhD, Ora Halutz, Nataliya Golishevski, MD, Moshe Binyamin, MD, Ruth Orkin, MD, Michael Hoffman, MD, Drorit Neumann, PhD, Moshe Mittelman, MD

Blood (2009) 114 (22): 1637.

https://doi.org/10.1182/blood.V114.22.1637.1637

Published: 2009

Journal Articles

Complement Deposition Is Predictive of a Low Absolute Immature Platelet Fraction in Immune Thrombocytopenic Purpura

Biree Andemariam, M.D., James B Bussel, Ellinor I.B. Peerschke, PhD

Blood (2008) 112 (11): 4534.

https://doi.org/10.1182/blood.V112.11.4534.4534

Published: 2008

Journal Articles

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement

Siao-Yi Wang, Emilian Racila, Ronald P. Taylor, George J. Weiner

Blood (2008) 111 (3): 1456–1463.

https://doi.org/10.1182/blood-2007-02-074716

Published: 2008

Journal Articles

Enhanced Serum Complement Activation on Platelets Is Associated with Arterial Thrombosis in Patients with Systemic Lupus Erythematosus (SLE) and Antiphospholipid Antibodies(aPL).

Ellinor I.B. Peerschke, PhD, Wei Yin, Ph.D., Deborah R. Alpert, M.D., Ph.D., Jane E. Salmon, M.D., Robert A.S. Roubey, M.D., Berhane Ghebrehiwet, D.V.M., D.Sc.

Blood (2007) 110 (11): 1637.

https://doi.org/10.1182/blood.V110.11.1637.1637

Published: 2007

Journal Articles

A Phase I Study of a Novel Human Monoclonal Antibody (mAb216) with Chemotherapy for the Treatment of Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

Michaela Liedtke, MD, Clare Twist, MD, Marcia Bieber, MD, Neelima Bhat, PhD, Nelson N.H. Teng, MD, PhD, Steven Coutre, MD

Blood (2007) 110 (11): 2831.

https://doi.org/10.1182/blood.V110.11.2831.2831

Published: 2007

Journal Articles

The C3b Component of Complement Inhibits NK Cell Activation Induced by Rituximab-Coated Target Cells.

Siao-Yi Wang, BA, Emilian Racila, MD, Ronald P. Taylor, PhD, George J. Weiner, MD

Blood (2006) 108 (11): 2505.

https://doi.org/10.1182/blood.V108.11.2505.2505

Published: 2006

Journal Articles

Primary Plasma Cells Expressing CD52 Are Efficiently Targeted In Vivo by Alemtuzumab.

Carmelo Carlo-Stella, MD, Massimo Di Nicola, MD, Paolo Longoni, Loredana Cleris, Marco Milanesi, Cristiana Lavazza, PhD, Raffaella Milani, MD, Matteo Carrabba, MD, Franca Formelli, PhD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2004) 104 (11): 3460.

https://doi.org/10.1182/blood.V104.11.3460.3460

Published: 2004

Journal Articles

An In Vitro Study of Antileukemic Serum

JOHN S. THOMPSON

Blood (1955) 10 (12): 1228–1235.

https://doi.org/10.1182/blood.V10.12.1228.1228

Published: 1955

NARROW

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Complement Inhibition with C1 Esterase Inhibitor Allowed Successful Transfusion of HLA Mismatched Platelets in a Transfusion Refractory Alloimmunized Patient: A Case Report

Antibody-Mediated Immunosuppression Can Result from RBC Antigen Loss Independent of Fcγ Receptors in Mice

C3 Modulates RBC Antigen to Negatively Regulate Antibody Response

Microbial Exposure Regulates the Development of Anti-Blood Group Antibodies

Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease

Complement Blockade with C1 Esterase Inhibitor in Refractory Immune Thrombocytopenia

N-Glycosylation Of Human ITP Autoantibodies Affects Complement Activation, Platelet Phagocytosis, and Platelet Survival In a Murine Model

Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo

GP IIb/Iiia-Dependent Complement Activation Is Common In Patients with Immune Thrombocytopenic Purpura.

Erythropoietin Treatment Is Associated with Augmented Immune Response to the Influenza Vaccine in Hematologic Patients.

Complement Deposition Is Predictive of a Low Absolute Immature Platelet Fraction in Immune Thrombocytopenic Purpura

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement

Enhanced Serum Complement Activation on Platelets Is Associated with Arterial Thrombosis in Patients with Systemic Lupus Erythematosus (SLE) and Antiphospholipid Antibodies(aPL).

A Phase I Study of a Novel Human Monoclonal Antibody (mAb216) with Chemotherapy for the Treatment of Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

The C3b Component of Complement Inhibits NK Cell Activation Induced by Rituximab-Coated Target Cells.

Primary Plasma Cells Expressing CD52 Are Efficiently Targeted In Vivo by Alemtuzumab.

An In Vitro Study of Antileukemic Serum

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only